Dickinson Andrew D's Form 4 filing
Gilead Sciences, Inc. (GILD) · filed Mar 12, 2025
- Accession no.
- 0001127602-25-009283
- Filed
- Mar 12, 2025
- Trade date
- Mar 10, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 6 non-derivative transactions and 5 derivative transactions. Open-market sales total $2.12M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Dickinson Andrew DCIK 0001310204 | Officer (Chief Financial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 10, 2025 | Common Stock | MOption exerciseAcquired | +4,916 | $63.91 | +$314,181.56 | 173,977 | Direct | |
| Mar 10, 2025 | Common Stock | MOption exerciseAcquired | +13,013 | $63.91 | +$831,660.83 | 186,990 | Direct | |
| Mar 10, 2025 | Common Stock | SSaleDisposed | −4,916 | $117.30F2 | −$576,646.8 | 182,074 | Direct | |
| Mar 10, 2025 | Common Stock | SSaleDisposed | −13,013 | $118.50F3 | −$1,542,040.5 | 169,061 | Direct | |
| Mar 10, 2025 | Common Stock | MOption exerciseAcquired | +7,968 | –F4 | – | 177,029 | Direct | |
| Mar 10, 2025 | Common Stock | FTax withholdingDisposed | −3,855 | $117.21 | −$451,844.55 | 173,174 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 10, 2025 | Common Stock | MOption exerciseDisposed | −4,916 | $0.00 | $0 | 13,013 | Direct | |
| Mar 10, 2025 | Common Stock | MOption exerciseDisposed | −13,013 | $0.00 | $0 | 0 | Direct | |
| Mar 10, 2025 | Common Stock | MOption exerciseDisposed | −7,968 | –F4 | – | 27,519 | Direct | |
| Mar 10, 2025 | Common Stock | AGrant or awardAcquired | +49,020 | $0.00 | $0 | 49,020 | Direct | |
| Mar 10, 2025 | Common Stock | AGrant or awardAcquired | +11,090 | –F4 | – | 38,609 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Sale prices reported for the transactions reported here range from $116.97 to $117.88. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.
Referenced by the price of 1 transaction in Table I.
- F3
Sale prices reported for the transactions reported here range from $118.00 to $118.80. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.
Referenced by the price of 1 transaction in Table I.
- F4
Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.
Referenced by the price of 1 transaction in Table I and 2 transactions in Table II.